Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6496 USD | +4.93% | -6.00% | +66.56% |
18/04 | Renalytix chief business officer to become president | AN |
18/04 | Renalytix Names Chief Business Officer as President | MT |
Business Summary
Number of employees: 102
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Artificial Intelligence-enabled in Vitro Diagnostics
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +26.61% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +26.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 15/18/15 |
James Sterling
DFI | Director of Finance/CFO | 54 | 15/18/15 |
Howard Doran
PSD | President | 63 | 01/23/01 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 15/18/15 |
Michael Donovan
CTO | Chief Tech/Sci/R&D Officer | 70 | 15/18/15 |
Joseph Hutson
PRN | Corporate Officer/Principal | - | 22/21/22 |
Sales & Marketing | - | 07/21/07 | |
Salim Hamir
SEC | Corporate Secretary | - | - |
Jed Fulk
SAM | Sales & Marketing | 64 | 07/21/07 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 30/21/30 |
Chairman | 72 | 15/18/15 | |
James McCullough
FOU | Founder | 56 | 15/18/15 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 15/18/15 |
Erik Lium
BRD | Director/Board Member | 56 | 01/18/01 |
Catherine Coste
BRD | Director/Board Member | 58 | 30/23/30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 154,368,191 | 99,307,151 ( 64.33 %) | 0 | 64.33 % |
Company contact information
Sector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.24% | 1.85TCr | |
-41.39% | 282.02Cr | |
+20.51% | 191.06Cr | |
-1.13% | 165.01Cr | |
+26.70% | 125.27Cr | |
-14.07% | 99Cr | |
-20.60% | 91Cr | |
+2.28% | 79Cr | |
-23.56% | 63Cr |
- Stock Market
- Equities
- RENX Stock
- RNLX Stock
- Company Renalytix Plc